文献速递肾小球疾病

白细胞介素-33加重过表达B细胞激活因子的转基因小鼠的IgA肾小球肾炎

Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor.
PubMed 文献 · J Am Soc Nephrol · 2022-04-06

该研究在过表达B细胞激活因子(BAFF)的转基因小鼠中给予白细胞介素-33(IL-33)或PBS,发现IL-33加重肾脏功能障碍、蛋白尿、肾小球硬化、小管间质损伤及IgA和C3沉积。IL-33扩增的2型先天淋巴样细胞(ILC2s)过继转移可加重肾炎,而去除ILC2s后该效应消失。作者认为IL-33和ILC2s值得作为人IgA肾病的可能介质进行评估。

要点

  • BAFF转基因小鼠给予IL-33后肾脏功能障碍和蛋白尿更严重。
  • IL-33处理增加BAFF转基因小鼠脾和肾脏CD19+ B细胞及肾和肠道ILC2s。
  • IL-33刺激的Rag1缺陷脾细胞过继转移加重肾炎和IgA沉积,去除ILC2s后不加重。

核心结论

  • IL-33扩增的ILC2s加重了小鼠模型中的IgA肾小球肾炎。
  • 这些发现表明IL-33和ILC2s值得作为人IgA肾病的可能介质进行评估。

研究设计与样本

  • 向野生型和BAFF转基因小鼠给予IL-33或PBS。
  • 用IL-33处理Rag1缺陷小鼠,联用或不联用抗CD90.2以优先去除ILC2s,分离脾细胞过继转移至BAFF转基因小鼠。

主要发现

  • BAFF转基因小鼠接受IL-33后出现更严重的肾脏功能障碍和蛋白尿、肾小球硬化、小管间质损伤及肾小球IgA和C3沉积。
  • 与野生型小鼠相比,BAFF转基因小鼠脾和肾脏CD19+ B细胞及肾和肠道ILC2s增加,给予IL-33后进一步增加。
  • 给野生型小鼠施用IL-33对肾功能或组织学无影响,也不改变脾、肾或肠道ILC2s数量。
  • 来自IL-33处理的Rag1缺陷小鼠的脾细胞过继转移加重BAFF转基因小鼠的肾小球肾炎和IgA沉积,而去除ILC2s(抗CD90.2)的脾细胞不加重。
  • 输注IL-33处理的Rag1缺陷脾细胞的野生型小鼠肾功能及ILC2s数量或分布无变化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cytokine IL-33 is an activator of innate lymphoid cells 2 (ILC2s) in innate immunity and allergic inflammation. B cell activating factor (BAFF) plays a central role in B cell proliferation and differentiation, and high levels of this protein cause excess antibody production, including IgA. BAFF-transgenic mice overexpress BAFF and spontaneously develop glomerulonephritis that resembles human IgA nephropathy. METHODS: We administered IL-33 or PBS to wild-type and BAFF-transgenic mice. After treating Rag1-deficient mice with IL-33, with or without anti-CD90.2 to preferentially deplete ILC2s, we isolated splenocytes, which were adoptively transferred into BAFF-transgenic mice. RESULTS: BAFF-transgenic mice treated with IL-33 developed more severe kidney dysfunction and proteinuria, glomerular sclerosis, tubulointerstitial damage, and glomerular deposition of IgA and C3. Compared with wild-type mice, BAFF-transgenic mice exhibited increases of CD19+ B cells in spleen and kidney and ILC2s in kidney and intestine, which were further increased by administration of IL-33. Administering IL-33 to wild-type mice had no effect on kidney function or histology, nor did it alter the number of ILC2s in spleen, kidney, or intestine. To understand the role of ILC2s, splenocytes were transferred from IL-33-treated Rag1-deficient mice into BAFF-transgenic mice. Glomerulonephritis and IgA deposition were exacerbated by transfer of IL-33-stimulated Rag1-deficient splenocytes, but not by ILC2 (anti-CD90.2)-depleted splenocytes. Wild-type mice infused with IL-33-treated Rag1-deficient splenocytes showed no change in kidney function or ILC2 numbers or distribution. CONCLUSIONS: IL-33-expanded ILC2s exacerbated IgA glomerulonephritis in a mouse model. These findings indicate that IL-33 and ILC2s warrant evaluation as possible mediators of human IgA nephropathy.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Wang YM, Shaw K, Zhang GY, et al. Interleukin-33 Exacerbates IgA Glomerulonephritis in Transgenic Mice Overexpressing B Cell Activating Factor. J Am Soc Nephrol. 2022. PMID: 35387873. doi:10.1681/ASN.2021081145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。